Ginsberg F, Famaey J P
Department of Rheumatology, Medicosurgical Centre Assubel, Brussels, Belgium.
J Int Med Res. 1991 Mar-Apr;19(2):131-6. doi: 10.1177/030006059101900206.
Percutaneous efficacy and tolerability of a new topical indomethacin spray compared with a corresponding placebo product were evaluated in a double-blind, randomized crossover study in 30 patients with tendinitis, i.e. 28 patients with peri-arthritis of the shoulder and two with epicondylitis. Each patient was treated with 4% indomethacin spray or the corresponding placebo product three to five times daily for a period of 14 days and then received the other treatment for the same period of time. The indomethacin spray demonstrated a clear efficacy compared with the placebo based on both objective criteria (elevation, abduction and internal rotation) and subjective criteria (spontaneous pain, pain on movement, pressure-induced pain, functional disturbances and sleep disturbances). Tolerability was excellent: only two patients had minor local cutaneous irritation with the indomethacin spray, which did not require interruption of treatment. Treatment with indomethacin spray appeared to be effective in 80% and well-tolerated in 93% of the patients studied.
在一项针对30名肌腱炎患者（即28名肩周炎患者和2名肱骨外上髁炎患者）的双盲、随机交叉研究中，评估了一种新型外用吲哚美辛喷雾剂与相应安慰剂产品相比的经皮疗效和耐受性。每位患者每天使用4%吲哚美辛喷雾剂或相应安慰剂产品三至五次，持续14天，然后在相同时间段接受另一种治疗。基于客观标准（抬高、外展和内旋）和主观标准（自发疼痛、运动时疼痛、压迫性疼痛、功能障碍和睡眠障碍），吲哚美辛喷雾剂与安慰剂相比显示出明显的疗效。耐受性极佳：只有两名患者使用吲哚美辛喷雾剂时有轻微的局部皮肤刺激，无需中断治疗。在所研究的患者中，使用吲哚美辛喷雾剂治疗的有效率为80%，耐受性良好率为93%。
